Key result
HER2 inhibitors strongly link to CVAEs, with trastuzumab and monoclonal antibodies showing the highest toxicity.
Why the study?
With widespread HER2 inhibitor use in cancer treatment, cardiovascular diseases induced by these agents have become a significant adverse event.
What is the profile and relative risk of cardiovascular adverse events associated with different classes of HER2 inhibitors?
Observational (n=12,398)
What is the profile and relative risk of cardiovascular adverse events associated with different classes of HER2 inhibitors?
Answers are grounded in this paper and cite their sources.
This large-scale pharmacovigilance analysis confirms the significant cardiovascular toxicity of HER2 inhibitors, particularly trastuzumab and other monoclonal antibodies, highlighting the need for careful cardiovascular monitoring in these patients.
Background: With the widespread use of human epidermal growth factor receptor 2 (HER2) inhibitors in cancer treatment, cardiovascular diseases induced by these agents have become a significant adverse event. Methods: We retrieved reports of HER2 inhibitor-induced cardiovascular adverse events (CVAEs) from the FDA Adverse Event Reporting System (FAERS) database, covering the period from the first quarter of 2004 to the fourth quarter of 2024. Disproportionality analyses were conducted using reporting odds ratios and proportional reporting ratios. The signals of HER2 inhibitor-related CVAEs were evaluated at both the standardized MedDRA query and preferred term levels. Results: A total of 12,698 reports associated with CVAEs were identified, with HER2 inhibitors listed as the primary suspected drug, involving 12,398 patients. Most cases were observed in individuals aged 45 and older, with a notably higher proportion in women. The time to onset of HER2 inhibitor-induced CVAEs showed certain variability. Trastuzumab exhibited higher cardiovascular toxicity compared with other HER2 inhibitors. In general, monoclonal antibodies demonstrated greater cardiovascular toxicity, whereas antibody-drug conjugates and HER2-tyrosine kinase inhibitors displayed comparable and lower effects. Conclusion: This pharmacovigilance analysis reveals a strong association between HER2 inhibitors and CVAEs, providing valuable insights for their prevention and clinical management.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2026) conducted an observational in HER2 inhibitor-induced cardiovascular adverse events (n=12,398). HER2 inhibitors vs. Other HER2 inhibitors was evaluated on Cardiovascular adverse events (CVAEs). HER2 inhibitors were strongly associated with cardiovascular adverse events in 12,398 patients, with trastuzumab and monoclonal antibodies exhibiting higher toxicity than other classes.
Synapse has enriched 10 related papers. Consider them for comparative context: